Jeffrey Bertolini, an officer of Carlsmed, Inc., filed a Form 144 notice of proposed sale of 243 shares of common stock on October 30, 2026, pursuant to Rule 144 under the Securities Act of 1933.

Key Highlights

  • Proposed sale: 243 shares of Carlsmed common stock with an aggregate market value of $3,839.40, according to the filing.
  • Acquisition method: The 243 shares were acquired on October 30, 2026, via a stock option exercise from the issuer, with cash payment on the same date.
  • Total shares outstanding: The filing lists 27,302,743 shares of common stock outstanding.
  • Rule 10b5-1 plan: The filing indicates a trading plan adoption date of March 12, 2026.
  • Prior three-month sales: Bertolini sold a combined 13,253 shares across seven transactions between July 30, 2026, and October 5, 2026, for aggregate gross proceeds as reported in the filing.
  • Broker named: Fidelity Brokerage Services LLC, 900 Salem Street, Smithfield, RI 02917, is listed as the executing broker.

Carlsmed Officer Proposes Sale Under Rule 144 on October 30, 2026

According to the Form 144 filing, Jeffrey Bertolini, identified as an officer of Carlsmed, Inc. (NASDAQ:CARL), proposed to sell 243 shares of the company's common stock with an aggregate market value of $3,839.40. The approximate date of sale listed in the filing is October 30, 2026. Carlsmed, Inc. is headquartered at 1800 Aston Avenue, Suite 100, Carlsbad, California 92008, and carries SEC File Number 001-42756.

The filing discloses that the 243 shares subject to the proposed sale were acquired on October 30, 2026, through a stock option exercise from the issuer, with cash as the nature of payment on the same date. The filing also notes reliance on a Rule 10b5-1 written trading plan, with a plan adoption date of March 12, 2026. The signing representation was made by Daniel Tucci as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for Bertolini.

The filing's three-month sales history for Bertolini lists seven prior transactions in Carlsmed common stock: 29 shares sold on July 30, 2026, for gross proceeds of $377.00; 10,449 shares on August 3, 2026, for $137,124.32; 787 shares on August 4, 2026, for $10,500.31; 242 shares on August 31, 2026, for $4,048.66; 746 shares on September 3, 2026, for $12,294.08; 243 shares on September 30, 2026, for $3,399.57; and 747 shares on October 5, 2026, for $10,749.33.

What Was Disclosed

Carlsmed officer Jeffrey Bertolini filed a Form 144 on October 30, 2026, notifying the SEC of a proposed sale of 243 shares of common stock acquired via stock option exercise, under a Rule 10b5-1 plan adopted March 12, 2026.